CATEGORY AUSTRALASIAN DENTIST 79 LINICAL What has gone under the radar? Teosyal Redensity 1 There has been a product in the Teoxane range called Teosyal Redensity 1 for some time. As a Teoxane Australian expert, I feel that this Hyaluronic acid gel has been very overlooked for far too long. All the interest has been in the volumizing and lifting dermal fillers on the market. Redensity 1 is a noncross-linked hyaluronic acid gel that contains a cocktail of 14 essential nutrients, including 8 amino acids (glycine, lysine, threonine, proline, isoleucine, leucine, valine, arginine), 3 anti-oxidants (glutathione, N-acetyl-L-cysteine, alphalipoic acid), 2 minerals (zinc and copper) and 1 vitamin (Vitamin B6). Essential amino acids cannot be made by the body, and instead must be supplied by the food or other supplements. So injecting this product into the skin ensures delivery of those essential nutrients exactly where they are needed. What does Redensity 1 do? Redensity 1 must also be injected into the superficial or mid-dermis so that it can deliver its result, which is a re-densification and rehydration of the face. Traditionally called a skinbooster, Redensity 1 is a little bit more than that. Unlike other products on the market, the addition of the amino acids and minerals makes this HA product a standout. I might be a bit biased, but the results do speak volumes. Your patient will notice an improvement in skin hydration, elasticity, texture and glow. I would recommend that treatment is performed once a month and at least twice to get the most benefit out of treatment. The practitioner can tailor treatment for the patient. Unlike traditional skinboosters that require 100’s of individual applications all over the face, Redensity 1 can be delivered strategically in the areas of most need, such as smokers lines, the lower face, preauricular area and upper cheek. Again, training is required to deliver this treatment, which should be focused on anatomy, technique and the product itself (ATP). Redensity 1 contains non-cross-linked high molecular weight hyaluronic acid (15mg/ml), along with some anaesthetic. This helps with patient comfort as you inject the product. Redensity 1 is delivered in either a 1ml or 3ml syringe. Similar to the “raised bubbles” described earlier, Redensity 1 also has some downtime. It takes around 24 hours for the injected bumps to disappear, working its way through the skin layers, delivering the results and essential nutrients to improve the skin as it does. Is Redensity 1 safe? Again, this product has been used globally and in Australia for many years, and has an impressive safety profile. When delivered in the right layer of the skin, there is an expected projection of HA in the skin until the product dissipates. Usually this takes around 24 hours, but in some patients has been reported to take up to 72 hours. Bruising can occur, but is usually minimal when the practitioner delivers the Redensity 1 into the upper dermis of the skin. Some patients may also experience some puffiness as HA will attract water into the skin however this is also a beneficial quality, rather than an adverse event. It should go without saying that any cosmetic injectable product should not be used without training to ensure that safety, anatomy and patient wellness is always respected. What is coming? Daxxify There is a new Botulinum Toxin coming soon called Daxxify. The pharmaceutical has just gained its FDA approval in September, and is currently being used in the USA and Europe. Similar to other neuromodulators, Daxxify works by modifying the release of Acetylcholine from the nerve ending to the muscle, so that the muscle contraction is softened or frozen altogether. What makes Daxxify exciting is that is has an increased longevity profile. Approximately 80% of people still had muscle relaxation at the 4 month mark, and around 50% of the participants in the trial had no lines or wrinkles in the treated area at the 6 month mark. Currently there are 3 other drugs on the ARTG register here in Australia, with most having a pharmaceutical effect for up to 3 to 4 months. This increased longevity that Daxxify promises will be a game-changer, particularly for those patients that have had great success in the relief of pain. Therapeutic use Neuromodulators are used for many therapeutic reasons, and commonly used as a treatment to soften tooth grinding and clenching. In those patients, the actual contraction of the muscle can cause tooth pain and breakage, as well as hypoxia in the muscle from over-use. The jaw joint itself will also suffer due to the constant pressure and wear-and-tear in a grinding patient. Neuromodulators are an option to reduce the symptoms and cycle of pain, and from my practical experience with my patients, it has been quite life-changing. Using Daxxify as the neuromodulator for these patients looks promising, as treatment will likely be required less often. However we will need to watch the overseas trends, reports and outcomes for now, as the drug is not yet available here in Australia. All indications are that other neuromodulators will probably be more appropriate initially, until the practitioner and patient have established the results and outcomes that they are happy with since botulinum toxin effects are not reversible. Daxxifywouldbemore appropriate touse as a second treatment to gain a longer-lasting effect. Again, we will watch this space as we learn more about this pharmaceutical from our global colleagues. u If you would like to learn more about the use of Botulinum Toxin and Dermal fillers, especially with the use of Profhilo and Redensity 1 treatments, visit: www.dermaldistinction.com
RkJQdWJsaXNoZXIy MTc3NDk3Mw==